

Eastbourne District General Hospital

Kings Drive Eastbourne East Sussex BN21 2UD

10th April 2024

4 ۱

FOI REF: 24/223

Tel: 0300 131 4500 Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

I have a Freedom of Information request regarding the treatment of certain types of cancer. Could you please answer the following questions:

How many patients were treated in the past 2 months for restric and restric

1)	oesophageal junction cancer (any stage) with:			
	•	CAPOX (Capecitabine with Oxalipla	tin).	6
	•	FOLFOX (Folinic acid, Fluorouracil	and Oxaliplatin).	7
	Lonsurf (Trifluridine - tipiracil).			0
	•	 Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine). 		
	 Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplati and Fluoropyrimidine (5-Fluorouracil or Capecitabine). 			1
	 Any other systemic anti-cancer therapy. Palliative care only. Section 12(1) applied, please see be 		гару.	32
			ow.	
		East Sussay Haalthaara NHS Trust	doop not controlly record nationto be	sing

East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

2) How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

•	Atezolizumab (Tecentriq).	9
•	Durvalumab (Imfinzi).	3
•	Nivolumab (Opdivo).	2
•	Pembrolizumab (Keytruda).	13
•	Chemotherapy.	51
•	Radiotherapy, ESHT does not deliver Radiotherapy. These patients	are

- Radiotherapy. ESHT does not deliver Radiotherapy. These patients are referred to University Hospitals Sussex NHS Trust.
- Chemotherapy AND Radiotherapy. Please see above.
- 3) In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

•	Avelumab + Axitinib (Bavencio + Inlyta).	6
•	Cabozantinib (Cometriq).	18
•	Nivolumab (Opdivo).	6
•	Nivolumab + Cabozantinib (Opdivo + Cometriq).	0
•	Nivolumab + Ipilimumab (Opdivo + Yervoy).	2
•	Pembrolizumab + Lenvatinib (Keytruda + Kisplyx)	3

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (<u>esh-tr.foi@nhs.net</u>), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department esh-tr.foi@nhs.net